InvestorsHub Logo
Followers 132
Posts 8441
Boards Moderated 1
Alias Born 06/01/2013

Re: None

Tuesday, 11/27/2018 1:30:26 PM

Tuesday, November 27, 2018 1:30:26 PM

Post# of 330244
The company intends to leverage these findings and resubmit the 510(k) application for a more specific indication: relief of musculoskeletal pain for women. Our sales data are compatible with the observation that women get substantial relief in that about 70% of our sales are to women.

Sree Koneru, VP of Product Development, expressed confidence in this strategy, both from a regulatory and marketability perspective. “We are also diligently proceeding with 510(k) applications for US market clearance of postoperative pain (RecoveryRx®) and menstrual pain (Allay®),” he added.